A Study to Evaluate the Safety of a Single Intravenous (IV) Dose of Orbactiv (Oritavancin) in Participants on Chronic Warfarin Therapy Being Treated For Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

NCT02452918 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

17

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Bacterial Skin and Skin Structure Infection

Interventions

DRUG: Oritavancin
DRUG: Warfarin

Sponsor

The Medicines Company